Sanofi (SNY) has released an update. Sanofi reported a robust 15.7% growth in sales for Q3 2024, driven by strong performances in its vaccine and pharmaceutical segments, notably with Dupixent ...

(Reuters) - French drug maker Sanofi on Friday posted stronger earnings growth than analysts had expected in the third quarter, helped by earlier-than-anticipated sales of seasonal vaccines.

Sanofi SAN-1.32%decrease; red down pointing triangle is in discussions with the French government to address concerns officials raised about a potential sale of a controlling stake in the company ...

PARIS (Reuters) -French unions have called on workers at Sanofi to strike from Thursday to protest a planned sale of the ...

Regeneron (REGN) and Sanofi (SNY) announced that the European Commission, or EC, has approved Dupixent to treat eosinophilic esophagitis, or ...

Sanofi on Friday said it’s in talks with the private equity firm CD&R to sell just over half of its consumer healthcare business, in a deal that could yield billions of dollars for the French ...

PARIS, Oct 11 (Reuters) - Sanofi (SASY.PA), opens new tab has entered into talks to sell a controlling 50% stake in its consumer health business Opella to U.S. private equity firm Clayton Dubilier ...

Oct 25 (Reuters) - French drug maker Sanofi (SASY.PA), opens new tab on Friday posted stronger earnings growth than analysts had expected in the third quarter, boosted by an earlier-than ...

PAI Partners has submitted an improved offer for Sanofi’s consumer health business, according to people familiar with the matter, an unexpected twist in one of the biggest deals in Europe this year.

Sanofi (NASDAQ:SNY) is close to a deal to sell its consumer health unit to private equity firm Clayton Dubilier & Rice for about €15 billion ($16.4 billion). A deal may be announced in the ...

(Reuters) - French drug maker Sanofi on Friday posted stronger earnings growth than analysts had expected in the third quarter, boosted by an earlier-than-anticipated start of the vaccination season.